• FDA cleared FoundationOne CDx as a companion diagnostic for EMD Serono’s TEPMETKO (tepotinib) to identify MET exon 14 skipping alterations in metastatic non-small cell lung cancer.
• The label expansion adds a tissue-based option alongside the previously cleared FoundationOne Liquid CDx blood test, broadening testing pathways for TEPMETKO eligibility.
• The approval leverages real-world evidence from more than 150,000 patients in the Flatiron Health-Foundation Medicine clinico-genomic database, marking the company’s first real-world data-powered companion diagnostic clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Foundation Medicine Inc. published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.